BHLHE22: A Non-Coding DNA Sequence Regulator of Cellular Processes

Target Name: BHLHE22

NCBI ID: G27319

BHLHE22

BHLHE22: A Non-Coding DNA Sequence Regulator of Cellular Processes

The Basic Helix-Loop-Helix (BHLHE) family is a group of non-coding DNA sequences that are characterized by a specific arrangement of DNA base pairs. BHLHE22 is a member of this family and is a key regulator of the cell cycle.

The BHLHE22 protein is a 22-kDa protein that is expressed in a variety of tissues and cells. It is highly conserved, with a calculated pI of 6.1 and a predicted localization in the cytoplasm. BHLHE22 is involved in the regulation of cell cycle progression, and is thought to play a role in the maintenance of cellular homeostasis.

BHLHE22 is a key regulator of the G1 phase of the cell cycle, which is critical for cell growth and division. During G1, BHLHE22 works to ensure that the cell prepares for cell division by regulating the expression of genes involved in cell growth and differentiation. This includes the regulation of the cyclin D1 gene, which encodes the protein cyclin D1.

BHLHE22 is also involved in the regulation of the G2 phase of the cell cycle, which is critical for the transition from cell proliferation to cell death. During G2, BHLHE22 helps to ensure that the cell prepares for cell division by regulating the expression of genes involved in cell growth and differentiation. This includes the regulation of the cyclin B1 gene, which encodes the protein cyclin B1.

In addition to its role in regulating the cell cycle, BHLHE22 is also thought to be involved in the regulation of cellular processes that are not directly related to the cell cycle. For example, BHLHE22 has been shown to be involved in the regulation of cell adhesion, and has been shown to interact with the protein cadherin.

BHLHE22 is also a potential drug target in cancer therapy. By targeting BHLHE22 with small molecules or other therapeutic agents, researchers may be able to inhibit the regulation of cell cycle progression and potentially inhibit the growth and spread of cancer cells.

Overall, BHLHE22 is a complex protein that is involved in a variety of cellular processes. Its role in the regulation of cell cycle progression and cellular processes beyond the cell cycle makes it a promising target for cancer therapy. Further research is needed to fully understand the mechanisms of BHLHE22 and its potential as a drug target.

Protein Name: Basic Helix-loop-helix Family Member E22

Functions: Inhibits DNA binding of TCF3/E47 homodimers and TCF3 (E47)/NEUROD1 heterodimers and acts as a strong repressor of Neurod1 and Myod-responsive genes, probably by heterodimerization with class a basic helix-loop-helix factors. Despite the presence of an intact basic domain, does not bind to DNA (By similarity). In the brain, may function as an area-specific transcription factor that regulates the postmitotic acquisition of area identities and elucidate the genetic hierarchy between progenitors and postmitotic neurons driving neocortical arealization. May be required for the survival of a specific population of inhibitory neurons in the superficial laminae of the spinal cord dorsal horn that may regulate pruritis. Seems to play a crucial role in the retinogenesis, in the specification of amacrine and bipolar subtypes. Forms with PRDM8 a transcriptional repressor complex controlling genes involved in neural development and neuronal differentiation

The "BHLHE22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BHLHE22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets